HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Update: 2025-10-14
Description
Featuring an interview with Dr Laura Huppert, including the following topics:
- General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00 )
- Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44 )
- Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30 )
- Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13 )
- Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25 )
- CNS penetration and activity of ADCs in the treatment of breast cancer (22:27 )
- Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24 )
- Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05 )
- Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51 )
- Ongoing evaluation of ADCs in the localized disease setting (35:42 )
- Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38 )
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
